Azitra, Inc. AZTR
At closeNov 6, 2026, 7:55 PM EST
After hours · Nov 6, 7:55 PM ET
- YTD
- -72.36%
- 1 year
- -83.24%
- Market cap
- 4.44M
- Revenue (ttm)
- 97.50K
- EPS (ttm)
- -2.80
- Shares out
- 7.63M
- Forward P/E
- -0.78
- YTD return
- -72.36%
- 1-year return
- -83.24%
- Volume
- 109.26K
- Avg volume
- 2.65M
- Open
- 0.749
- Previous close
- 0.7251
- Day's range
- 0.719 – 0.7799
- 52-week range
- 0.72 – 4.37
- Price target
- 3.50 (+377.8%)
5D -0.0363 (-4.72%)
Key statistics
- Enterprise value
- -3.45M
- PEG ratio
- 0.00
- Price / sales
- 31.91
- Price / book
- 0.39
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -6.56M
- Total cash
- 7.26M
- Total debt
- 643.35K
- Return on equity
- -134.85%
- Short % of float
- 3.09%
- 50-day average
- 0.49486
- 200-day average
- 2.79
Analyst view
- Target (low)
- 3.00
- Target (mean)
- 3.50
- Target (high)
- 4.00
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.50.
Financials — quick view
About Azitra, Inc.
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- azitrainc.com
News
Azitra Expands Eligibility For Ongoing Phase 1/2 Clinical Trial Of ATR04-484 To Include Individuals With Rash Associated With KRAS And MEK Inhibitors 
Why Celestica Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket 
Azitra Suspends ATM Offering Program For The Foreseeable Future; From September 28, 2026 - October 26, 2026, The Company Sold An Aggregate Of 1,000 Shares Of Common Stock Under The ATM Program For Aggregate Gross Proceeds Of ~$126 
Azitra To Present Progress For Its Cosmetic ATR-COSF Program Targeting Fine Lines And Wrinkles At Bio-europe, November 10; First-In-Human Study With ATR-COSF Initial Results Anticipated By End Of 2026 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
12 Health Care Stocks Moving In Tuesday's After-Market Session - 12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Azitra Regains NYSE American Compliance
Your note
Sign in to keep a note on AZTR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAYER HEALTHCARE L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jun 20, 2023 | 0 |
| FLETCHER AARON G.L. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 20, 2023 | 0 |
| KREIS LESLIE W JR | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 20, 2023 | 0 |
| MCCLARY ANDREW | Director | Conversion of Exercise of derivative security | Jun 20, 2023 | 0 |
| SALVA FRANCISCO D | Chief Executive Officer | Purchase | Feb 12, 2024 | 338,300 |
| STASKEY NORM | Chief Financial Officer | Purchase | Mar 27, 2024 | 51,100 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Warberg Asset Management LLC | 0.64% | 48,804 | 19.91K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.45% | 34,159 | 13.94K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.36% | 27,100 | 11.06K | Sep 29, 2024 |
| Virtu Financial LLC | 0.28% | 21,314 | 8.70K | Sep 29, 2024 |
| National Bank of Canada/FI | 0.07% | 5,000 | 2.04K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.01% | 799 | 325 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.35% | 26,600 | 10.85K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 7,561 | 3.08K | Oct 30, 2024 |